Loading...
Please wait, while we are loading the content...
Similar Documents
Balsalazide led to greater remission rates and tolerance than mesalamine in acute ulcerative colitis.
| Content Provider | Semantic Scholar |
|---|---|
| Author | Hanauer, S. B. |
| Copyright Year | 1999 |
| Abstract | Patients 101 patients who were 18–80 years of age and had symptomatic (moderate or severe) grade 2 to 4 ulcerative colitis that extended >12 cm beyond the anal margin. Exclusion criteria were Crohn’s disease, idiopathic proctitis, noninflammatory bowel diseases, stool parasites, toxins, pathogens, use of steroids within the previous month, use of immunosuppressive agents in the previous 3 months, daily use of a rectal steroid to maintain remission, or use of mesalamine releasing compound releasing >1.2 g/day in the previous 14 days. Follow up was 98% (mean age 41 y, 63% men). |
| Starting Page | 455 |
| Ending Page | 455 |
| Page Count | 1 |
| File Format | PDF HTM / HTML |
| Alternate Webpage(s) | http://gut.bmj.com/content/gutjnl/44/4/455.full.pdf |
| PubMed reference number | 10075949v1 |
| Volume Number | 44 |
| Issue Number | 4 |
| Journal | Gut |
| Language | English |
| Access Restriction | Open |
| Subject Keyword | Anus Feces Immune thrombocytopenic purpura Immunosuppressive Agents Intestinal Diseases Intestines Parasites Patients Proctitis Steroids TUBE,RECTAL,24FR,PLASTIC B#6510 Testosterone 5-alpha-Reductase Toxin Ulcer Ulcerative Colitis balsalazide mesalamine pediatric acute myeloblastic leukemia |
| Content Type | Text |
| Resource Type | Article |
